Remission and dropout rate of anti-VEGF therapy for age-related macular degeneration

European Journal of Ophthalmology

Volumn 21, Issue 6, 2011, Pages 777-782

  Oishi, Akio ^a   Mandai, Michiko ^a,b   Nishida, Akihiro ^a   Hata, Masayuki ^a   Matsuki, Takaaki ^a   Kurimoto, Yasuo ^a  

^a KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

^b RIKEN   (Japan)

Author keywords

Age related macular degeneration; Pegaptanib; Ranibizumab

Indexed keywords

PEGAPTANIB; RANIBIZUMAB; VERTEPORFIN;

AGED; ARTICLE; COMBINATION CHEMOTHERAPY; DRUG TOLERABILITY; FEMALE; HUMAN; INJECTION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MONOTHERAPY; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; REMISSION; RETINA MACULA AGE RELATED DEGENERATION; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; VISUAL ACUITY;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; APTAMERS, NUCLEOTIDE; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MALE; PATIENT DROPOUTS; PHOTOCHEMOTHERAPY; REMISSION INDUCTION; RETROSPECTIVE STUDIES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 80054123885     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.5301/EJO.2011.7430     Document Type: Article

References (21)

1. Rosenfeld PJ, Brown DM, Heier JS, et al, MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-1431.
2. Brown DM, Kaiser PK, Michels M, et al, ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1432-1444.
3. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T, ANCHOR Study Group. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009; 116: 57-65.
4. Bressler NM. Antiangiogenic approaches to age-related macular degeneration today. Ophthalmology 2009; 116(Suppl): S15-S23.
5. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration: results of a randomized clinical trial: Macular Photocoagulation Study Group. Arch Ophthalmol 1991; 109: 1220-1231.
6. Laser photocoagulation of subfoveal recurrent neovascular lesions in age-related macular degeneration: results of a randomized clinical trial: Macular Photocoagulation Study Group. Arch Ophthalmol 1991; 109: 1232-1241.
7. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials: TAP report. Arch Ophthalmol 1999; 117: 1329-1345.
8. Hawkins BS, Bressler NM, Miskala PH, et al. Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: ophthalmic findings: SST report no. 11. Ophthalmology 2004; 111: 1967-1980.
9. Marcus DM, Peskin E, Maguire M, et al, AMDRT Research Group. The age-related macular degeneration radiotherapy trial (AMDRT): one year results from a pilot study. Am J Ophthalmol 2004; 138: 818-828.
10. Brown DM, Regillo CD. Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients. Am J Ophthalmol 2007; 144: 627-637.
11. Regillo CD, Brown DM, Abraham P, et al. Randomized, double- masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 2008; 145: 239-248.
12. Mitchell P, Korobelnik JF, Lanzetta P, et al. Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br J Ophthalmol 2010; 94: 2-13.
13. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007; 143: 566-583.
14. Dadgostar H, Ventura AA, Chung JY, Sharma S, Kaiser PK. Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration. Ophthalmology 2009; 116: 1740-1747.
15. Rovner BW, Casten RJ. Activity loss and depression in agerelated macular degeneration. Am J Geriatr Psychiatry 2002; 10: 305-310.
16. Mitchell J, Bradley C. Quality of life in age-related macular degeneration: a review of the literature. Health Qual Life Outcomes 2006; 4: 97.
17. Potter MJ, Szabo SM. One-year outcomes after photodynamic therapy in patients with age-related macular degeneration with poor baseline visual acuity. Graefes Arch Clin Exp Ophthalmol 2006; 244: 1026-1028.
18. Azab M, Benchaboune M, Blinder KJ, et al. Verteporfin therapy of subfoveal choroidal neovascularization in age-relatedmacular degeneration: meta-analysis of 2-year safety results in three randomized clinical trials: Treatment Of Age-Related Macular Degeneration With Photodynamic Therapy and Verteporfin In Photodynamic Therapy Study Report no. 4. Retina 2004; 24: 1-12.
19. George S, Cooke C, Chakravarthy U. Exudative AMD subtypes and eligibility for treatment with ranibizumab. Eye 2010; 24: 1247-1251.
20. Falkenstein IA, Cochran DE, Azen SP, et al. Comparison of visual acuity in macular degeneration patients measured with Snellen and early treatment diabetic retinopathy study charts. Ophthalmology 2008; 115: 319-323.
21. Holz FG, Korobelnik JF, Lanzetta P, et al. The effects of a flexible visual acuity-driven ranibizumab treatment regimen in age-related macular degeneration: outcomes of a drug and disease model. Invest Ophthalmol Vis Sci 2010; 51: 405-412.